期刊
NUTRIENTS
卷 11, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/nu11061196
关键词
carnosine; L-histidine; beta-alanine; brain; cognition; treatment; psychiatry; neurology; nervous system
资金
- SAIA (Slovak Academic Information Agency)
- Peter Doherty Biomedical Research fellowship by the National Health and Medical Research Council (NHMRC) of Australia
- National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship [APP1059660, APP1156072]
- National Heart Foundation Future Leader Fellowship [100864]
- NIHR Sheffield Biomedical Research Centre (BRC)/NIHR Sheffield Clinical Research Facility (CRF)
- [APVV 15-0253]
- [VEGA 2/0107/18]
- [SAS-MOST JRP 2018/10]
Neurological, neurodegenerative, and psychiatric disorders represent a serious burden because of their increasing prevalence, risk of disability, and the lack of effective causal/disease-modifying treatments. There is a growing body of evidence indicating potentially favourable effects of carnosine, which is an over-the-counter food supplement, in peripheral tissues. Although most studies to date have focused on the role of carnosine in metabolic and cardiovascular disorders, the physiological presence of this di-peptide and its analogues in the brain together with their ability to cross the blood-brain barrier as well as evidence from in vitro, animal, and human studies suggest carnosine as a promising therapeutic target in brain disorders. In this review, we aim to provide a comprehensive overview of the role of carnosine in neurological, neurodevelopmental, neurodegenerative, and psychiatric disorders, summarizing current evidence from cell, animal, and human cross-sectional, longitudinal studies, and randomized controlled trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据